A Phase 3 interventional study of BCD-131 (pegdarbepoetin beta) and Mircera (methoxypolyethylene glycol-epoetin beta) in Anemia, Chronic Kidney Disease and Chronic Kidney Disease Patients on Hemodialysis, sponsored by Biocad. Active, not recruiting at 14 sites in Russia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Biocad · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney disease (CKD) patients on dialysis.
This study is designed to test the hypothesis that BCD-131 is non-inferior to Mircera for the treatment of anemia in patients with end-stage renal disease on dialysis, with the primary assessment occurring at Weeks 28-32 of treatment. Eligible subjects will have Stage 5 Chronic Kidney Disease (CKD) and will have been receiving dialysis (a minimum frequency of 3 sessions per week and at least 12 hours per week of standard hemodialysis, with a stable dialysis prescription) for at least 90 days prior to informed consent form (ICF) signature. Subjects must have anemia of renal origin with no other identifiable causes of anemia (including anemia of chronic disease, vitamin B12 deficiency, folic acid deficiency, or iron deficiency, etc.).
This study evaluates the efficacy of BCD-131 as maintenance therapy. Eligible patients must have received stable doses of erythropoiesis-stimulating agents (erythropoietin alfa, erythropoietin beta, or darbepoetin alfa) for at least 3 months prior to ICF signature and throughout the screening period, with target hemoglobin levels (100-120 g/L) maintained for at least 2 weeks prior to and at the time of screening.
The study comprises the following periods:
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
This study's planned enrollment of 228 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Browse Anemia studies →Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BCD-131 (pegdarbepoetin beta)
Biological: BCD-131 (pegdarbepoetin beta)
Mircera (methoxypolyethylene glycol-epoetin beta)
Biological: Mircera (methoxypolyethylene glycol-epoetin beta)
BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 84 weeks
Mircera (methoxypolyethylene glycol-epoetin beta), subcutaneous injection; regimen: once every 4 weeks up to Week 48 inclusive; starting from Week 52, all subjects will be switched to BCD-131 treatment up to Week 84 inclusive.
Proportion of subjects (%) with the target hemoglobin level (100-120 g/L inclusive)
Time frame: During the assessment period at Weeks 28-32
Proportion of subjects (%) with the target hemoglobin level (100-120 g/L inclusive)
Time frame: Weeks 48-52
Proportion of subjects (%) with a mean hemoglobin level at the time of assessment within the range of ±10 g/L from baseline
Time frame: Weeks 28-32
Proportion of subjects (%) who required dose adjustment of the test drug/reference drug during the maintenance therapy stage of the main study period
In the main study period, a dose adjustment is expected during the first 12 weeks of therapy (titration phase), and a maintenance therapy stage is expected during the subsequent weeks of the main study period.
Time frame: Weeks 12-32
Proportion of subjects (%) who required dose adjustment of the test drug/reference drug during the extension study period
Time frame: Weeks 33-52
Proportion of subjects (%) who required blood transfusion during the main study period
Time frame: Weeks 0-32
Proportion of subjects (%) who required blood transfusion during the entire study
Time frame: Weeks 0-52
The mean hemoglobin level during the main study period
Time frame: Weeks 0-32
The mean hemoglobin level during the entire study
Time frame: Weeks 0-52
Proportion of subjects (%) with hemoglobin values greater than 130 g/L and with values greater than 140 g/L during the main study period
Time frame: Weeks 0-32
Proportion of subjects (%) with hemoglobin values greater than 130 g/L and with values greater than 140 g/L during the entire study
Time frame: Weeks 0-52
Proportion of subjects with reported AEs/SAEs, which, according to the investigator, are related to the study drugs
Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88
Proportion of subjects in each group who developed CTCAE v. 5.0 grade 3-4 AEs, which, in the investigator's opinion, are related to the use of the study drugs
Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88
Proportion of subjects in each group who prematurely withdrew due to AEs/SAEs
Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88
Frequency of arterial and venous thrombotic complications (cerebrovascular accident, vascular access thrombosis, etc.)
Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88
Frequency of non-fatal myocardial infarction, death from cardiovascular diseases, death from any cause
Time frame: Weeks 0-32, Weeks 32-52, Weeks 52-88
The Proportion of BAb- and NAb-positive Patients
Blood sampling for immunogenicity assessment (binding antibodies \[BAbs\] or neutralizing antibodies \[NAbs\]) will be performed before the first injection (Week 0) and then at Weeks 12, 24, 36, and 52
Time frame: Weeks 0, 12, 24, 36, 52, 64, 76
Proportion of subjects (%) with a mean hemoglobin level at the time of assessment within the range of ±10 g/L from baseline
Time frame: Weeks 48-52
Proportion of subjects (%) with the target hemoglobin level (100-120 g/L inclusive)
Time frame: Weeks 80-84
Proportion of subjects (%) who required dose adjustment of the investigational product after switching from Mircera to BCD-131
The switch from Mircera to BCD-131 occurs at Week 52, followed by a 12-week titration period during which dose adjustments are expected. This titration period is excluded from the assessment of this outcome measure.
Time frame: Weeks 64-84
Proportion of subjects (%) who required blood transfusion after switching from Mircera to BCD-131
Time frame: Weeks 52-84
Mean hemoglobin level
Time frame: Weeks 52-84, Weeks 0-84
Proportion of subjects (%) with hemoglobin levels of >130 g/L and >140 g/L
Time frame: Weeks 52-84, Weeks 0-84
Ran from Mar 2025 to primary completion in May 2026, 14 months.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 14 months is below that.
Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.